TPP1 and prostate cancer: The results show in Figure 3E that SOCS2, EGR1, TPP1, and C11orf54 had significant lower expression in Tregs excavated from prostate cancer patients compared to those excavated from healthy donors, while RRM2 was significantly overexpressed in prostate cancer (Figure 3E), suggesting that RRM2 was a risk factor in our TILTregSig for prostate cancer patients.